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In this work the enhancing effect of cyclodextrins on the buccal permeation of a hydrophobic model drug,
omeprazole was studied. First, the influence of the complexation with cyclodextrins in the absence and in
the presence of an alkali agent, L-arginine, on the drug stability was checked at neutral conditions since
omeprazole alone is only stable in basic conditions. In vitro transbuccal permeation of omeprazole
non-complexed and complexed with b- and methyl-b-cyclodextrin and in presence of L-arginine was
examined using freshly obtained porcine buccal mucosa. Tissue viability after incubation with sample
solutions was assessed using a MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) bio-
chemical assay and histological evaluation. The toxicity of the sample solutions on buccal mucosa was
evaluated by measuring lactate dehydrogenase activity. The present results show that complexation with
cyclodextrins increases drug stability at neutral conditions; furthermore, L-arginine contributed to higher
drug stability. Permeation studies indicate an increase on drug permeation in complexed form of 1.1- and
1.7-fold for b-cyclodextrin and methyl-b-cyclodextrin, respectively. The presence of L-arginine increases
drug permeation 1.4-fold in omeprazole complexed with b-cyclodextrin and 2.4-fold in the inclusion
complex formed with methyl-b-cyclodextrin. The cell viability of the buccal mucosa after a 3 h incubation
period, with all sample solutions, remained around 70% and lactate dehydrogenase assay showed that
studied cyclodextrins, even in the presence of an alkali agent are not cytotoxic for porcine buccal mucosa.
Histological evaluation of the tissue demonstrated that the buccal epithelium remains viable after 3 h of
incubation with sample solutions.
 2008 Elsevier B.V. All rights reserved.1. Introduction
Buccal mucosa is a potential site for drug absorption in alterna-
tive to oral drug delivery. Active molecules administered through
the buccal mucosa pass directly into the systemic circulation,
thereby minimizing the first hepatic pass and adverse gastro-intes-
tinal effects [1,2]. Other important advantages are the low enzy-
matic activity, suitability for drugs or excipients that mildly and
reversibly damage or irritate the mucosa, painless administration,
easy drug withdrawal, facility to include permeation enhancer/en-
zyme inhibitor or pH modifier in the formulation and versatility in
designing as multidirectional or unidirectional release systems for
local or systemic actions [3]. However, lower permeability of the
buccal mucosa to large molecules can be problematic in order to
achieve therapeutic levels of such molecules. Buccal permeation
can be increased by using various penetration enhancers. Recently,ll rights reserved.
tical Technology, Faculty of
mbra, Portugal. Tel.: +351cyclodextrins have been classified as a new class of penetration
enhancers [4–6]. These molecules are cyclic oligosaccharides with
a hydrophilic outer surface and a hydrophobic central cavity. The
hydrophilic exterior of the cyclodextrin molecules makes them
water-soluble while the hydrophobic cavity provides a microenvi-
ronment for appropriate sized non-polar molecules [7]. Cyclodex-
trins are able to form dynamic molecular inclusion complexes
with many drugs by incorporating the drug molecule, or com-
monly a lipophilic moiety of the molecule, into the central cavity
[8]. These non-covalent complexes offer a variety of physicochem-
ical advantages over the unmodified drugs such as the possibility
to increase their water solubility and stability [9]. It is generally
recognized that cyclodextrins act as true carriers by keeping the
hydrophobic drug molecules in solution and deliver them to the
surface of the biological membrane, where they partition into the
membrane [10]. Cyclodextrins can enhance drug permeation by
increasing drug availability and stability at the surface of the bio-
logical barriers [11]. However, derivative cyclodextrins, especially
methylated cyclodextrins, act as absorption enhancers by different
pathways. These hydrophobic cyclodextrins act as absorption
enhancers, probably, by transiently changing membrane perme-
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junctions [12]. During cell differentiation process in buccal muco-
sa, small organelles called membrane coating granules (MCGs)
composed of non-lamellar lipid sacks are formed in intercellular
spaces of the non-keratinized regions [13,14]. These MCGs, first
observed in epidermis, are not different from those observed in
the skin and are believed to provide an intercellular permeability
barrier to buccal mucosa [15]. Methyl-b-cyclodextrin, a more
hydrophobic cyclodextrin, can permeate the buccal mucosa and
to form inclusion complexes with hydrophobic molecules, namely
lipids from the cellular membrane, interacting strongly with these
lipids; it could modify buccal mucosa permeability and could act as
penetration enhancer for the buccal route.
Omeprazole (OME) a substituted benzimidazole, has been
shown to effectively suppress gastric acid secretion by inhibiting
the H+K+-ATPase (proton pump), in the parietal cells [16,17]. The
bioavailability of OME following oral administration is usually very
low, since it degrades quickly in the acidic environment of the
stomach and undergoes hepatic first-pass metabolism. As an
attempt to improve the oral bioavailability of OME various oral for-
mulations have been developed over the years. However, these oral
formulations revealed to have a large intra-individual variation in
drug plasma concentration in human subjects [18,19].
The aim of this study is to evaluate the potential enhancement
effect of the cyclodextrins on the buccal mucosa permeation of
OME. Inclusion complexes between OME and both cyclodextrins in
absence and in presence of an alkali agent, L-arginine (ARG), were
prepared by a freeze-drying method [20]. The effect of
b-cyclodextrin (bCD) and methyl-b-cyclodextrin (MbCD) in the
absence and in the presence of ARG on the OME stability was
assessed at neutral conditions by high performance liquid chroma-
tography (HPLC). Permeation studieswere performedusing two dif-
ferent cyclodextrins, a natural cyclodextrin, bCD and a methylated
derivative, MbCD, in order to compare their permeation enhancing
properties. Viability, integrity and cytotoxicity studies were carried
out to investigate possiblemorphologic changes of the buccalmuco-
sa, after contact with the complexed OME in the absence and pres-
ence of ARG. Structural alterations in the buccal mucosa were also
considered and supported by histological studies.2. Materials and methods
2.1. Materials
bCD (Beta-cyclodextrin, KLEPTOSE, Mw = 1135) and MbCD
(Methyl-b-cyclodextrin, CRYSMEB, Mw  1190, with an average
degree of substitution of 0.5) were kindly donated by Roquette
(Lestrem, France) and Omeprazole (OME, Mw = 345.42) was kindly
donated by Belmac Laboratory, S.A. (Madrid, Spain). L-Arginine
(ARG) was purchased from Panreac (Santiago de Compostela,
Spain). Thiazolyl blue tetrazolium bromide (MTT), fluorescein iso-
thiocyanate-dextran 40 (FD40, average Mw 40.000) were pur-
chased from Sigma (St. Louis, MO, USA). The cytotoxicity
detection kit (Dye solution + Catalyst) was purchased from Roche.
All other reagents (chemicals and solvents) were of analytical
grade.
2.2. Preparation of inclusion complexes
Solid inclusion complexes were prepared by freeze-drying
method. Systems were prepared in a stoichiometry 1:1
(drug:cyclodextrin) according to previous phase solubility studies
[21] and ARG was added in a molar proportion 6:1, relatively to
OME. The same systems were prepared in the absence of ARG to
observe the influence of the alkali agent on the drug stability andpermeation. All the clear solutions were frozen by immersion in
an ethanol-bath at 50 C (Shell Freezer, Labconco, Freezone
model 79490) and the frozen solutions were lyophilized in a
freeze-dryer (Lyph-lock 6 apparatus, Labconco) for 72 h.
2.3. Stability studies
The stability of OME alonewas checked at three different pH val-
ues: 7.0, 7.9 and 9.0. After, stability of OME alone, complexed with
bCD or MbCD in absence and in presence of ARG was examined at
37 C in 40 mM of Bis–Tris buffer (bis[2-hydroxyethyl]imino–
tris[hydroxymethyl]methane) at pH 7.0 ± 0.5. Solutions containing
100 lg/mL of OME in free and complexed state were prepared.
These solutions were stirred at 300 rpm during 8 h at 37 C.
Samples were collected every hour and analyzed by HPLC.
2.4. High performance liquid chromatography (HPLC)
The official HPLC method described in the USP XXX [22] was
used for quantification of the drug. An Elite Lachrom Liquid Chro-
matograph (Merck, Hitachi) system consisting of a quaternary
pump (L2130), with a L2450 programmable multiple wavelength
detector set at 300 nm and an autosampler L2200 was used. The
separation was carried out at room temperature and the column
used was a reverse-phase Purospher RP-18 endcapped (5 lm),
125 cm  4 mm. The mobile phase was a mixture of phosphate
buffer (pH 7.6 ± 0.5) and acetonitrile (75:25, v/v), filtered through
0.20 lm nylon filters, degassed and pumped at a constant flow rate
of 1 mL min1. The chromatograms were recorded and the peak
area response was measured using an automatic integrator. The
injection volume was 20 ll for all standards and samples.
2.4.1. Validation of the HPLC method
The HPLC method was validated by using the following analyt-
ical parameters: linearity, precision, accuracy, repeatability and
specificity. Linearity was evaluated by calculation of a regression
line using the least squares method. Calibration curve was
obtained from eight standard solutions, containing 0.7, 1.5, 3, 6,
12.5, 25, 50 and 100 lg/mL of OME in Bis–Tris buffer injected three
times. Precision was determined by injecting six times the stan-
dard solution containing 12.5 lg/mL of OME. Accuracy was tested
using three different standard solutions containing 6, 12.5 and
25 lg/mL of OME injected three times. The repeatability was per-
formed by six standard solutions containing 12.5 lg/mL of OME
prepared six times and injected. Specificity was determined by
comparing the following solutions: 100 lg/mL of OME alone, in
the presence of bCD or MbCD and in the presence of bCD or MbCD
and ARG injected three times each. At last, the interference of deg-
radation products with OME peak retention time was checked by
injection of two different solutions containing 100 lg/mL of
OME. In one solution, OME was submitted to degradation in acidic
conditions and in the other solution, OME was degraded by high
temperatures (60 C during 1 h). The final pH of all solutions was
adjusted to 7.0 ± 0.5 and relative standard deviations (RSD) were
calculated.
2.5. In vitro permeation studies in porcine buccal mucosa
2.5.1. Tissue preparation
Porcine buccal mucosa was used as it resembles much better
the human buccal mucosa regarding permeability, barrier lipid
composition, histology and ultrastructural organization [23]. Buc-
cal mucosa from pigs weighing 70–100 kg was obtained freshly
from a local slaughterhouse and it was used at least within 3 h
after animal slaughtering. Most of the underlying tissue was
removed from the mucosa with surgical scissors. The buccal tissue
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Fig. 1. Stability studies of OME in 40 mM of Bis–Tris buffer at different pH values.
Each value is the mean of three independent assays (±SD, n = 3).
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dermatome (Aesculap Accu Dermatome, Germany).
2.5.2. Permeation studies
In vitro permeation studies were conducted in Ussing chambers
with a diffusion area of 0.64 cm2 and a compartment volume of
1 mL. All experiments were performed at 37 C and protected
against light. Dermatomed porcine buccal mucosa was mounted
between the donor and the acceptor chambers, which were filled
with 40 mM of Bis–Tris buffer at pH 7.0 ± 0.5 and allowed to equil-
ibrate for 15 min. The donor chamber was emptied after the equil-
ibration period and replaced with 1 mL of a solution containing
300 lg/mL of OME alone, complexed OME with cyclodextrins
(bCD and M bCD) and complexed OME with cyclodextrins in pres-
ence of ARG. Every 30 min, 100 lL samples were withdrawn from
the acceptor chamber and replaced by 100 lL of Bis–Tris buffer at
pH 7.0 and equilibrated at 37 C. Samples were analyzed by HPLC
in order to determine the amount of permeated OME. Cumulative
corrections were made for the previously removed samples.
The apparent permeability coefficients (Papp) for free and com-
plexed OME were calculated according to the following equation:
Papp = Q/(A  c  t), where Q is the total amount permeated
within the incubation time (lg); A is the diffusion area of the Us-
sing chamber (cm2); c is the initial concentration of OME in the
donor chamber (lg/cm3); t is the total time of the experiment (s).
The cumulative amount of permeated drug was plotted versus
time, and the steady state flux (Jss) was calculated using the
formula:
Jss = DM/(A.Dt), where DM is the amount of drug transported
across the membrane during the time Dt and A is the diffusional
area.
2.6. Integrity studies
FD40 [impermeable fluorescein isothiocyanate (FITC)-labeled
dextran] was added to the donor chamber after the permeability
measurements (concentration 10 mg/mL), and quantified in the
receptor chamber, after 1 h by fluorescence spectroscopy. Concen-
trations of FD40 were determined using a fluorescence spectrome-
ter Infinite M200 TECAN, at an excitation wavelength of 495 nm
and emission wavelength of 515 nm.
2.7. Viability studies
Samples of buccal mucosa of pig were cut, weighed and
immersed in Bis–Tris buffer at pH 7.0 ± 0.5 (negative control), in
solutions containing inclusion complexes between OME and two
cyclodextrins (bCD and MbCD) in the absence and presence of
ARG and in a solution with 2% (v/v) of Triton, used as positive con-
trol. Samples were incubated at 37 C and 300 rpm during 3 h. MTT
was dissolved (2 mg/mL) in fresh prepared buffer and filtered
through a filter of 0.45 lm to remove any dissolved crystals. After
3 h, 1 mL of MTT solution was added to each sample and the sam-
ples were placed on a rotating platform (300 rpm) at 37 C for 2 h.
After this time, the MTT solution was removed and the tissue was
rinsed twice with 1 mL of buffer for 1 min and then minced with
surgical scissors. To extract the water insoluble formazan, 2 mL
of DMSO was added to each sample and stirred (300 rpm) for
80 min at 37 C. The absorbance of formazan was measured at
540 nm (with DMSO as a blank) with the spectrophotometer
Infinite M200 TECAN.
2.8. Cytotoxicity studies
The same procedure used in viability studies to prepare the
samples was carried out. Samples were incubated at 37 C whilestirred at 300 rpm during 3 h. Each hour a sample was removed
and stored at 4 C. All the samples were centrifuged at 5000 rpm
during 2 min to remove possible interferences. Afterwards 50 lL
of each solution was mixed with 50 lL of a specific reagent (Cyto-
toxicity Detection Kit, Dye solution + Catalyst). Final solutions
were incubated at slow stirring for 30 min. The absorbance was
measured at 496 nm with a spectrophotometer Infinite M200
TECAN.
2.9. Histological studies
Buccal tissues were cut with the electrical dermatome and incu-
bated at 37 C in vials containing Bis–Tris buffer pH 7.0 ± 0.5, OME
solution, complexed OME with cyclodextrins in the absence and
presence of ARG and in a solution of Triton 2% (v/v). After 3 h,
tissue samples were immersed in trypan blue solution during
20 min [25]. After that, samples were washed with buffer and fixed
in Bovins solution (300 mL of picric acid, 100 mL of formaldehyde
and 20 mL of acetic acid). A sample of buccal mucosa, extracted
after slaughtering the animal, was used as control and transferred
directly to the trypan blue solution and fixed in Bovins solution
without any previous incubation. Tissue sampleswere thenwashed
and dehydrated with a series of isopropanol grades ranging from
70% to absolute isopropanol, methylbenzoate, chloroform and final-
ly samples were embedded in paraffin. Paraffin preparations were
cut into slices and examined under an Olympus BH2 light micro-
scope. The magnification of the microscope used was 10.
2.10. Data analysis
Statistical data analysis was performed using the t-test with
p < 0.05 as the minimal level of significance. The statistical analysis
was done using GraphPad Prism version 4.00 software. All exper-
iments were run at least in triplicate.
3. Results and discussion
3.1. Stability studies
The OME stability in solution was studied in 40 mM of Bis–Tris
buffer at different pH values (Fig. 1). After 3 h it was observed that
4% of the OME was degraded at pH 7.0 and 7.9. After 8 h, the
remaining drug at pH 7.0, 7.9 and 9.0 was 78%, 87% and 100%,
respectively. This study confirms that OME degrades at neutral
342 A. Figueiras et al. / European Journal of Pharmaceutics and Biopharmaceutics 71 (2009) 339–345conditions [26–28]. However, basic conditions are not suitable for
drug delivery in physiological membranes. For that reason it is nec-
essary to increase drug stability at neutral conditions in order to
develop a pharmaceutical formulation with OME for administra-
tion in buccal mucosa.
The stability profiles of OME alone and complexed with bCD and
MbCD in the absence and presence of ARG are depicted in Fig. 2.
Prior to start the stability studies, the pH of all solutions was
adjusted to 7.0 in order to observe the real effect of the inclusion
complexation in the absence and presence of ARG in OME stability.
After 3 h the remaining drug calculated was 99% in the drug com-
plexed with MbCD in the presence of ARG and 97% in the OME
complexed with bCD in presence of ARG. In the inclusion complex
formed in the absence of ARG the remaining drug achieved was
97% for both cyclodextrins and 96% in the case of the drug alone.
These results show that after 3 h the complexation with cyclodex-
trins cannot significantly increase OME stability. However, when
the drug was complexed with MbCD in the presence of ARG, it
was not degraded at all during this period of time. The same result
was not obtained for the inclusion complex formed with bCD in the
presence of ARG. At the end of the study the remaining amount of
drug in the solutions containing the drug alone, OME complexed
with bCD and MbCD and the inclusion complexes with ARG, was
determined to be 78%, 83%, 84%, 86% and 91%, respectively. These
values indicate that the inclusion of OME in the cyclodextrin cavity
increases the OME stability. Nevertheless, in the presence of ARG
the improvement on drug stability was more pronounced, espe-
cially when the drug was complexed with MbCD. Previous studies
have reported [21] that OME forms a more stable inclusion
complex with the MbCD than with the bCD due to the greater
hydrophobic character of the former. Stability studies performed
with OME in the presence of ARG at pH 7.0 (data not shown) could
not increase OME stability suggesting that ARG alone acts as an
alkali agent. These results propose that some interactions can oc-
cur between ARG and the inclusion complex. Consequently, ARG
can stabilize the inclusion complex formed between OME and
cyclodextrins, resulting in increased drug stability at neutral
conditions.70
75
80
85
90
95
100
0 60 120 180 240 300 360 420 480
time (minutes)
re
m
a
in
in
g 
dr
ug
 (%
)
OME_pH=7.0
IC_BCD_pH=7.0
IC_MBCD_pH=7.0
IC_BCD_ARG_pH=7.0
IC_MBCD_ARG_pH=7.0
Fig. 2. Stability studies of free and complexed OME with cyclodextrins (bCD and
MbCD) in absence and in presence of ARG in 40 mM of Bis–Tris buffer at pH
7.0 ± 0.5. Each value is the mean of three independent assays (±SD, n = 3). Inclusion
complex between OME and bCD (IC_BCD); inclusion complex between OME and
MbCD (IC_MbCD); inclusion complex between OME and bCD in presence of ARG
(IC_BCD_ARG) and inclusion complex between OME and MbCD in presence of ARG
(IC_MBCD_ARG).3.2. Validation of the HPLC method
The calibration curve and regression coefficient for the pro-
posed method were: Y = 203742X  140888 and R2 = 0.9998 indi-
cating a good linearity in the range of the study. The R2 obtained
was higher than 0.999, as frequently recommended [29]. RSD
values calculated are showed in Table 1. The results show a good
precision, accuracy, repeatability and specificity of the analytical
method. At last, results confirm that the presence of cyclodextrins
(bCD andMbCD), alkali agent (ARG) or degradation products do not
interfere with the retention time corresponding to OME peak.
3.3. Permeation studies
In vitro permeability studies are an useful tool to assess the
potential of a localized anatomical site as a route for drug delivery.
However, in vitro conditions should simulate the in vivo situation
as closest possible.
The permeability profiles of OME alone, complexed with bCD
and MbCD and complexed OME in presence of ARG, are shown in
Fig. 3A and B. Table 2 contains apparent permeability coefficients
(Papp) and flux values of the different studied systems. The cumu-
lative amount of complexed OME with bCD absorbed over 3 h
through epithelium was only 1.1-fold greater than the amount of
absorbed OME alone. In OME complexed with MbCD the increase
in drug absorbed was 1.4-fold compared to the OME alone. These
results suggest that bCD acts as a carrier, keeping the hydrophobic
OME molecules in solution and delivering them to the surface of
the buccal mucosa. In the case of MbCD, the enhancement in drug
absorption indicates that this cyclodextrin acts as an enhancer of
permeation by different mechanisms as reported in the literature
[11,12]. Lipophilic cyclodextrins such as MbCD, can permeate bio-
membranes, interact with the lipids and increase drug uptake
through the buccal mucosa. Permeation studies with OME com-
plexed with both cyclodextrins (bCD and MbCD) in the presence
of ARG show an enhancement of 1.7- and 2.4-fold, respectively,
when compared with the amount of absorbed OME alone. This fact
suggests that beyond the permeation enhancement effect of the
cyclodextrins, the presence of ARG can stabilize the inclusion com-
plex formed and, this stabilizing effect of the OME at the biomem-
brane surface increases the amount of OME available to permeate
the buccal epithelium. On the other hand, a recent study [30]
shows that the poly-L-arginine can act as an enhancer of the muco-
sal epithelia permeability by positively charged amino groups,
interacting with negatively charged sites on the epithelial mem-
brane and tight junctions. At neutral conditions, ARG is in the
cationic form being able to interact with negatively charged mole-
cules situated in the mucus layer [31] on the surface of the buccalTable 1
RSD values of the analytical parameters used to validate the HPLC method
Standard solution (lg/mL) RSD %
Precision (n = 6)
12.5 2.207
Accuracy (n = 9)
6 2.515
12.5 0.715
25 0.599
Repeatibility (n = 6)
12.5 3.454
Specificity (n = 9)
100 3.314
100 + bCD 0.721
100 + MbCD 0.247
100 + bCD + ARG 0.308
100 + MbCD + ARG 0.979
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Fig. 4. Cell viability in porcine buccal mucosa measured by MTT assay expressed as
the mean values obtained from three inserts (±SD, n = 3). (1) Buccal mucosa after
3 h exposed to Bis–Tris buffer 40 mM (positive control); (2) buccal mucosa after 3 h
exposed to Triton 2% (v/v; negative control); (3) buccal mucosa after 3 h exposed to
OME_bCD inclusion complex in solution; (4) buccal mucosa after 3 h exposed to
OME_MbCD inclusion complex in solution; (5) buccal mucosa after 3 h exposed to
OME_bCD inclusion complex in ARG solution; (6) buccal mucosa after 3 h exposed
to OME_MbCD inclusion complex in ARG solution; *all these samples are statisti-
cally different compared to the sample exposed to Triton 2% (v/v), (p < 0.05).
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Fig. 3. In vitro permeation studies in porcine buccal mucosa of free and complexed
OME with bCD (A) and MbCD (B) in the absence and in presence of ARG solution.
Each value is the mean of three assays (±SD, n = 3).
Table 2
Apparent permeability coefficients (Papp) and flux values of different studied systems
Systems Papp (cm/s) Ratioa Flux (lg/cm2 h)
OME 1.883E06 ± 7.692E08 1.0 2.382 ± 0.185
IC OME_bCD 2.143E06 ± 3.638E08 1.1 2.685 ± 0.092
IC OME_MbCD 2.702E06 ± 1.040E07 1.4 3.455 ± 0.217
IC OME_bCD + Arg 3.269E06 ± 1.900E08 1.7 4.161 ± 0.117
IC OME_MbCD + Arg 4.445E06 ± 2.686E07 2.4 5.588 ± 0.564
Indicated values are means (±SD, n = 3–4).
a Enhancement ratio = Papp (sample)/Papp (control).
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performed with OME in presence of ARG (data not shown) was ob-
served a 1.2-fold increase in the amount of permeated drug in
presence of ARG compared to the amount of OME alone permeated.
In the integrity studies, fluorescence values calculated for all the
systems after 1 h of incubation with a solution containing 10 mg/
mL of FD40, indicated a concentration of FD40 in the acceptor
chamber below 0.01%. This data suggests that the tissue integrity
of buccal mucosa is maintained during the permeation studies.
The principle here is that FD40 being a very large molecule, cannot
permeate the buccal mucosa and enter the acceptor chamber
unless the mucosa is damaged.
3.4. Viability studies
The MTT assay has been used for quantitative colorimetric
measurements of mammalian cell survival and proliferation. The
original assay has been modified to assess the viability of the tissue
specimens [32].MTT is converted in viable cells to formazan (a dark purple
water insoluble compound) by enzymes in active mitochondria
collectively known as tetrazolium reductase and the amount of
formazan generated is directly proportional to the number of living
cells [33]. The results of cell viability (%) after 3 h of incubation of
porcine buccal mucosa with samples solutions, negative and posi-
tive control are shown in Fig. 4. To calculate the percentage of cell
viability, sample in Bis–Tris buffer (negative control) was used as
100% of cellular viability. It was observed that cell viability of the
buccal mucosa after 3 h of incubation remained around 70% in all
samples as compared to Bis–Tris buffer (negative control). By con-
trast, Triton 2% (v/v) treated cells displayed a significant decrease
(p < 0.05) of viability after 3 h of incubation (around 30%) when
compared with negative control and all sample solutions.
3.5. Cytotoxicity studies
Cell death is typically assayed by quantifying plasmamembrane
damage and in recent years, lactate dehydrogenase (LDH) activity
has been used in toxicological studies in mucosal membranes
[34,35]. LDH is a stable cytoplasmic enzyme which is present in
all cells. When the plasmatic membrane is damaged, LDH is rapidly
released into the supernatant medium and its activity can be deter-
mined by a colorimetric reaction. In the first step NAD+ is reduced
to NADH/H+ by the LDH-catalyzed conversion of lactate to pyru-
vate. In the second step, a catalyst added to the supernatant med-
ium (diaphorase) transfers H/H+ from NADH/H+ to the tetrazolium
salt, which was reduced to a formazan dye. An increase in the
number of dead or plasma membrane-damaged cells leads to an
increased LDH activity in the supernatant medium, which directly
correlates with the amount of formazan produced. Therefore, the
amount of dye produced is proportional to the number of lysed
(dead or plasmatic membrane damaged) cells [36].
Methylated b-cyclodextrins interact strongly with lipids [11],
for that reason, cell membrane integrity was evaluated by quanti-
fication of the LDH released. Until 1 and 3 h, no significant differ-
ences in LDH activity (absorbance of formazan/mg of tissue)
were observed in the samples incubated with inclusion complexes
between OME and both cyclodextrins (bCD and MbCD) in absence
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Fig. 5. Formazan absorbance resultant of LDH activity released from porcine buccal
mucosa after 1 and 3 h exposed to: (1) Bis–Tris buffer 40 mM; (2) Triton 2% (v/v)
solution; (3) OME_bCD inclusion complex in solution; (4) OME_MbCD inclusion
complex in solution; (5) OME_bCD inclusion complex in ARG solution; (6)
OME_MbCD inclusion complex in ARG solution.
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40 mM (Fig. 5). At the same time, the sample exposed to Triton 2%
(v/v) showed a significant increase in the absorbance of formazan
between 1 and 3 h (p < 0.05). These results demonstrate that cyclo-
dextrins, namely bCD and MbCD even in presence of an alkali
agent, ARG, do not present cytotoxic effects to the porcine buccal
mucosa when compared with Triton solution.
3.6. Histological studies
Fig. 6 shows the photomicrographs of the buccal epithelium
after slaughter the animal, 3 h after incubation at 37 C with Bis–
Tris buffer pH 7.0 ± 0.5, OME alone, complexed with cyclodextrins
in the absence or presence of ARG and in a solution of Triton 2%
(v/v), which is known to be extensively toxic [37]. In some
photomicrographs it was possible to observe a separation of the
epithelium from the connective tissue and only the buccal epithe-
lium is present [38]. Histological studies showed that after 3 h ofFig. 6. Light microscopic view of buccal mucosa extracted after slaughtering the animal
complexed OME with bCD and MbCD in solution (d and e); complexed OME with bCD an
(magnification, 10).incubation with sample solutions there were no cell leakage and
no visible changes in the thickness of the superficial layer was ob-
served, indicating that the buccal epithelium appeared viable when
compared with the tissue incubated with buffer or the tissue re-
moved immediately after death of the animal. Only few cells in
the superficial layer of some preparations appeared to be dead,
probably due to the mechanical stress during tissue preparation.
However, the thickness of the buccal epithelium was greatly re-
duced after 3 h exposed to a Triton solution. Treatment of buccal
epithelium with this solution resulted in cellular changes and tis-
sue necrosis probably due the detergent effect of this compound.
These histological results support data obtained in the viability
and cytotoxicity studies.
4. Conclusion
Buccal drug delivery offers an alternative to conventional oral
administration for drugs that show low stability at acidic condi-
tions of the stomach and a strong first hepatic effect. However,
buccal mucosa represents an effective absorption barrier and
new strategies must be found to overcome it. The effect of cyclo-
dextrins to increase OME stability and permeability through the
buccal epitheliumwas studied and the integrity, viability and cyto-
toxicity effects were evaluated after the exposition of the buccal
tissue with this kind of permeation enhancers. Stability studies
performed at neutral conditions suggested that the complexation
of OME increased drug stability and in the presence of ARG this ef-
fect was improved. The in vitro transbuccal permeation of OME
was enhanced in the presence of cyclodextrins. This increase was
highest with MbCD indicating that this lipophilic cyclodextrin
can permeate buccal mucosa and consequently to enhance drug
delivery through the biomembrane. The complexation of OME with
MbCD in presence of ARG increases drug permeation 2.4-fold, sug-
gesting that ARG favors drug permeation due to the establishment
of ionic interactions with negative charges present in mucus layer
on the surface of the mucosa. Viability studies showed that buccal
mucosa remains viable after 3 h incubation period with OME in
complexed form in absence and in presence of ARG. These results
were supported by histological evaluations. No toxicity effects(a) control; 3 h after incubation at 37 C with: Bis–Tris buffer (b), OME solution (c),
d MbCD in presence of ARG in solution (f and g) and 2% (v/v) of Triton solution (h),
A. Figueiras et al. / European Journal of Pharmaceutics and Biopharmaceutics 71 (2009) 339–345 345were observed in buccal mucosa after incubation with OME com-
plexed with cyclodextrins even in the presence of ARG. The results
presented here demonstrate that complexation of OME with MbCD
in presence of ARG may be promising approach to increase drug
stability and permeation through the buccal mucosa, that ulti-
mately can result in improve drug bioavailability.
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